These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 17127172)

  • 1. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
    Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
    Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
    Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ
    Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.
    Panjideh H; Da Silva Coelho VC; Dernedde J; Bachran C; Förster GJ; Franke J; Fasold P; Fuchs H; Thiel E; Deckert PM
    Int J Oncol; 2008 Apr; 32(4):925-30. PubMed ID: 18360720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
    Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
    Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
    Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
    Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
    Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
    Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with (177)Lu for potential use in radioimmunotherapy.
    Lee SY; Hong YD; Pyun MS; Felipe PM; Choi SJ
    Appl Radiat Isot; 2009; 67(7-8):1185-9. PubMed ID: 19324558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
    Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of 211At-labeled humanized monoclonal antibody A33.
    Almqvist Y; Steffen AC; Lundqvist H; Jensen H; Tolmachev V; Sundin A
    Cancer Biother Radiopharm; 2007 Aug; 22(4):480-7. PubMed ID: 17803442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
    Schoffelen R; van der Graaf WT; Franssen G; Sharkey RM; Goldenberg DM; McBride WJ; Rossi EA; Eek A; Oyen WJ; Boerman OC
    J Nucl Med; 2010 Nov; 51(11):1780-7. PubMed ID: 21051650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
    Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.